VitaResc Acquisition Of Apex To Fund Septic Shock Treatment Phase III Study
Executive Summary
The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' lead product, pyridoxalated hemoglobin polyoxyethylene.
You may also be interested in...
Baxter Pays $150 Mil. For Somatogen Recombinant Hemoglobin Technology
Baxter will pay about $150 mil. for a chance to apply Somatogen's recombinant hemoglobin technology to its blood substitute program.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials